Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

RenovoRx (RNXT) Gains from Sales and Divestitures (2024 - 2025)

RenovoRx (RNXT) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $4032.0 as the latest value for Q4 2025.

Quarterly Gains from Sales and Divestitures fell 19.36% to $4032.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4032.0 through Dec 2025, down 19.36% year-over-year, with the annual reading at $4032.0 for FY2025, 19.36% down from the prior year.
Gains from Sales and Divestitures hit $4032.0 in Q4 2025 for RenovoRx, down from $4.0 million in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $4.0 million in Q3 2025 to a low of $4032.0 in Q4 2025.